Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Learning Objectives: After completing this course, the reader will be able to: Assess stereotactic body radiation therapy (SBRT) as an emerging modality in the treatment of oligometastatic patients.Discuss data on safety and efficacy of SBRT in the oligometastatic setting.Evaluate SBRT as a competitive option in patients with a low burden of disease in the metastatic setting. CME This article is available for continuing medical education credit at CME.TheOncologist.com In patients with proven distant metastases from solid tumors, it has been a notion that the condition is incurable, warranting palliative care only. The term “oligometastases” was coined to refer to isolated sites of metastasis, whereby the entire burden of disease can be recognized as a finite number of discrete lesions that can be potentially cured with local therapies. Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient and tumor immobilization, image guidance, and treatment planning and delivery. A number of studies, both retrospective and prospective, showed promising results in terms of local tumor control and, in a limited subset of patients, of survival. This article reviews the radiobiologic, technical, and clinical aspects of SBRT for various anatomical sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718 · cited 1×
“tially result in substantial direct and indirect cost savings [64].”
BackgroundMetastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital
Lam, K. ‐., & Lo, C. ‐. (2002) · Clinical Endocrinology · doi:10.1046/j.0300-0664.2001.01435.x · Cited by 469 · cited 3×
“One of the most interesting studies was recently published by Sher et al. [65], who performed a cost-effectiveness analysis of SBRT versus RFA for patients with medically inoperable, early-stage NSCLC.”
BackgroundInfluential
Cited by
MR-guidance in clinical reality: current treatment challenges and future perspectives
Corradini, S., Alongi, F., Andratschke, N., Belka, C., Boldrini, L., Cellini, F., Debus, J., Guckenberger, M., Hörner-Rieber, J., Lagerwaard, F. J., et al. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1308-y · Cited by 356
Self-citation
Metadata
- Authors
- Alongi, F., Arcangeli, S., Filippi, A. R., Ricardi, U., & Scorsetti, M.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06-20
- Volume
- 17
- Issue
- 8
- Pages
- 1100-1107
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2113258467
- Cited by
- 209
- References
- 2
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. https://app.cochat.ai/papers/10.1634/theoncologist.2012-0092
- The paper
- Alongi, F., Arcangeli, S., Filippi, A. R., Ricardi, U., & Scorsetti, M. (2012). Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. The Oncologist. https://doi.org/10.1634/theoncologist.2012-0092
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.